Identification of new SNPs associated with severe toxicity to capecitabine

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pharmacological Research

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.phrs.2017.03.021PMID 28347776
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio

  2016cited by this paper
• Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.

  2016cited by this paper
• Clinical implementation of pharmacogenetics

  2016cited by this paper
• Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

  2015cited by this paper
• Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial

  2015cited by this paper
• Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer

  2015cited by this paper
• Cost Considerations in the Evaluation and Treatment of Colorectal Cancer

  2015cited by this paper
• Correction: Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines

  2015cited by this paper
• Polymorphisms in the DUSP10 gene are associated with sex-specific colorectal cancer risk in a Han population.

  2015cited by this paper
• Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.

  2015cited by this paper
• Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.

  2014cited by this paper
• A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS

  2014cited by this paper
• Identification of genetic variants associated with capecitabine-induced hand–foot syndrome through integration of patient and cell line genomic analyses

  2014cited by this paper
• Functional annotation of colon cancer risk SNPs

  2014cited by this paper
• Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma.

  2014cited by this paper
• Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer

  2014cited by this paper
• Role of solute carrier transporters in pancreatic cancer: a review.

  2014cited by this paper
• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2014cited by this paper
• Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

  2014cited by this paper
• [Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients].

  2014cited by this paper
• Two novel type 2 diabetes loci revealed through integration of TCF7L2 DNA occupancy and SNP association data

  2014cited by this paper
• High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy.

  2014cited by this paper
• DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.

  2013cited by this paper
• Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

  2013cited by this paper
• Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines

  2013cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

  2013cited by this paper
• Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer

  2012cited by this paper
• Select Your SNPs (SYSNPs): a web tool for automatic and massive selection of SNPs

  2012cited by this paper
• Systems pharmacology assessment of the 5-fluorouracil pathway.

  2011cited by this paper
• Combinations of Polymorphisms in Genes Involved in the 5-Fluorouracil Metabolism Pathway Are Associated with Gastrointestinal Toxicity in Chemotherapy-Treated Colorectal Cancer Patients

  2011cited by this paper
• A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

  2011cited by this paper
• Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

  2011cited by this paper
• [Practical Guide to genetic association studies. Considerations for its clinical use].

  2009cited by this paper
• A second generation human haplotype map of over 3.1 million SNPs

  2007cited by this paper
• Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.

  2006cited by this paper
• Systemic therapy for metastatic colorectal cancer: current options, current evidence.

  2005cited by this paper

• A Pharmacogenomic Basis for Tolerance of 5-Fluorouracil Following Early, Severe Toxicity from Capecitabine in a CDA Ultrarapid Metabolizer Colon Cancer Patient: A Case Report.

  2026influential citation
• P06-16 Impact of citidin deaminase genetic variants on capecitabine toxicity

  2025cites this paper
• Development of an Early-Warning Model for Predicting the Capecitabine-Induced Diarrhea

  2025cites this paper
• Precision medicine on a budget in Africa: using existing genetic data to mitigate adverse drug reactions to conventional cancer drugs

  2025cites this paper
• Endoplasmic reticulum transporter OAT2 regulates drug metabolism and interaction.

  2024cites this paper
• Impact of TYMS gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients – identification of novel single nucleotide polymorphism: Cross-sectional study

  2024cites this paper
• Advancements in current one-size-fits-all therapies compared to future treatment innovations for better improved chemotherapeutic outcomes: a step-toward personalized medicine

  2024cites this paper
• Methylenetetrahydrofolate Reductase (MTHFR) Variants and Severe Capecitabine Toxicity: A Case Report and Review of Literature

  2024cites this paper
• Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism

  2024cites this paper
• Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.

  2023cites this paper
• Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?

  2023cites this paper
• [Translated article] Genetic variants and enzyme activity in citidin deaminase: Relationship with capecitabine toxicity and recommendation for dose adjustment.

  2023cites this paper
• Genetic variants and enzyme activity in citidin deaminase: Relationship with capecitabine toxicity and recommendation for dose adjustment.

  2023cites this paper
• Thymidine phosphorylase as a molecular target for quercetin-incorporated collagen matrix in the prevention of hand-foot syndrome induced by capecitabine in rats.

  2023cites this paper
• Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review

  2023influential citation
• Inhibiting uptake activity of organic anion transporter 2 by bile acids.

  2022cites this paper
• Detection of relevant pharmacogenetic information through exome sequencing in oncology.

  2022cites this paper
• Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.

  2022cites this paper
• Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers

  2022influential citation
• Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile.

  2022cites this paper
• Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with DPYD Genetic Polymorphism: A Systematic Review and Meta-Analysis

  2022cites this paper
• An Evaluation of the Diagnostic Accuracy of a Panel of Variants in DPYD and a Single Variant in ENOSF1 for Predicting Common Capecitabine Related Toxicities

  2021cites this paper
• Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine

  2021cites this paper
• Purine and Pyrimidine Metabolism

  2021cites this paper
• Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer

  2020cites this paper
• A case–control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine‐induced gastrointestinal toxicity

  2020cites this paper
• A Case-Control Study on the Correlation Between Thymidylate Synthase Gene Polymorphisms and Raltitrexed Treatment Combined with Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Treatment

  2020cites this paper
• Role of Genetic Variations in the Hepatic Handling of Drugs

  2020cites this paper
• New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine

  2020cites this paper
• DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation

  2020cites this paper
• Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine

  2020cites this paper
• The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?

  2020cites this paper
• The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines

  2019influential citation
• The role of pharmacogenomics in adverse drug reactions

  2019cites this paper
• The genetic landscape of the human solute carrier (SLC) transporter superfamily

  2019cites this paper
• CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy

  2019cites this paper
• Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients

  2019cites this paper
• Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.

  2019cites this paper
• Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: an IPD meta-analysis.

  2019cites this paper
• Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition

  2018cites this paper
• Genetic and Epigenetic Determinants of Environmental Injury and Disease

  2018cites this paper
• Clinical implications of genetic variation in carboxylesterase drug metabolism

  2018cites this paper
• Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan

  2018cites this paper
• Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.

  2018cites this paper
• Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients

  2018cites this paper
• Epigenetics and MicroRNAs in Pharmacogenetics.

  2018cites this paper
• Using pharmacogenetics to prevent severe adverse reactions to capecitabine.

  2017cites this paper